The Allergology Service of the Hospital Universitario de Cuenca, part of Spain’s Castilla-La Mancha health service (Sescam), has presented a new immunotherapy vaccine for cat allergy at an international allergy symposium in Gran Canaria — the first such presentation in Spain, announced this month, according to Telecinco.
Dr. Antonio Moreno, head of the hospital’s Allergology Service, presented the results of a study conducted at the Cuenca hospital during the International Symposium of the Spanish Society of Allergology and Clinical Immunology (SEAIC). The symposium ran from October 28 to 31, 2026, and brought together more than 1,100 allergy specialists from around the world.
The regional government of Castilla-La Mancha, in a press release, said the research "highlights the scientific and care potential" of the Cuenca hospital and places it "on the map of medical research and innovation" in allergology.
But patients should temper expectations. As the sources report, no availability date has been announced, no detailed efficacy or safety results have been made public, and the composition, route of administration, and dosing schedule of the vaccine have not been disclosed. This is a research advance, not a treatment patients can request today.
Vaccine remains unapproved and unpublished
- A Spanish hospital team has developed and presented a cat-allergy vaccine, but it is not yet approved or available.
- No efficacy numbers, safety data, or treatment schedule have been published yet — those details decide whether it matters clinically.
- Existing cat-allergy immunotherapies already exist; the open question is whether this one offers real advantages.
Why cat allergy strains patients and clinics
Cat allergy is triggered mainly by proteins found in the animal’s skin, saliva, and secretions. In sensitized people, the immune system mistakes these proteins for a threat and mounts a disproportionate response, producing rhinitis, conjunctivitis, and, in more severe cases, asthma. The sources note that in some patients this considerably limits quality of life.

In plain terms: antihistamines and inhalers dampen the reaction; immunotherapy tries to retrain the immune system so the reaction happens less in the first place.
Conventional allergy vaccines use preparations containing the allergen itself, administered in a controlled way to build tolerance. Their effectiveness varies with the type of allergy, the preparation used, and the patient’s characteristics.
What is confirmed — and what is not
The confirmed facts are these: a study was completed at the Hospital Universitario de Cuenca, its results were presented in Gran Canaria by Dr, according to Lacerca. Moreno, and the hospital’s allergology team currently participates in seven multicenter clinical trials, which the regional government says has consolidated the service as a reference point in clinical research.
What remains open: no marketing authorization, no availability date, no published data on clinical efficacy, adverse effects, or which patient profile might benefit. Determining the advance’s real value will require seeing the study’s results and checking whether the treatment outperforms immunotherapies already in use.
| Item | Status | Source |
|---|---|---|
| Vaccine developed and study completed | Confirmed | Sources |
| Presented at SEAIC symposium, Oct 28–31, 2026 | Confirmed | Sources |
| More than 1,100 specialists attended the forum | Confirmed | Sources |
| Seven multicenter clinical trials ongoing at the service | Confirmed | Sources |
| Efficacy and safety data | Not yet public | Sources |
| Availability date or regulatory approval | Not announced | Sources |
Presentation is not an available treatment
There is an important regulatory gap between a conference presentation and a medicine. A therapy shown at a scientific symposium must still pass formal regulatory review before it can reach allergy clinics. No such step has been announced for this vaccine.
That distinction matters for the roughly 1,100 specialists who heard the data and for the patients who read headlines about a cat allergy vaccine. The honest framing, supported by the reporting: this is a promising research milestone from a regional Spanish hospital, with its scientific value still to be established through published results.
Contraindications & When to Consult a Doctor
Generally, specific immunotherapy of any kind is prescribed and supervised by an allergist, and people with uncontrolled asthma, certain cardiovascular conditions, or a history of severe systemic reactions to immunotherapy require individualized risk assessment before starting such treatment.
Anyone whose cat allergy causes wheezing, chest tightness, or breathing difficulty should consult a physician now, rather than waiting for a vaccine that has no availability date. Existing management options — allergen avoidance, antihistamines, nasal corticosteroids, and already-approved immunotherapies — remain the current standard of care.
A small hospital with a growing research footprint
Beyond the vaccine itself, the story is about where the science came from. Dr. Moreno called the international presentation a recognition of the work of the Cuenca service, and the regional government framed it as evidence that healthcare professionals in the province can generate scientific knowledge and contribute to advances in allergic disease treatment.
The next meaningful step, on the record, is publication of the study’s detailed results — the point at which clinicians and regulators can judge whether this immunotherapy changes practice. Until then, the advance stays where the sources place it: presented, promising, and not yet available.
References
- Spanish Society of Allergology and Clinical Immunology (SEAIC), International Symposium, Gran Canaria, October 28–31, 2026.
- Servicio de Salud de Castilla-La Mancha (Sescam) / Junta de Castilla-La Mancha press release, November 2026.
Readers should consult a qualified healthcare professional regarding diagnosis and treatment of allergies.